NF-κB, stem cells and breast cancer: The links get stronger

Breast Cancer Research

Volumn 13, Issue 4, 2011, Pages

  Shostak, Kateryna ^a   Chariot, Alain ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HER2 PROTEIN, HUMAN;

BREAST CANCER; BREAST EPITHELIUM; CANCER CELL; CANCER STEM CELL; HUMAN; NONHUMAN; PATHOGENESIS; REVIEW; STEM CELL; ANIMAL; BREAST TUMOR; CELL SURVIVAL; EPITHELIUM CELL; EXPERIMENTAL NEOPLASM; FEMALE; METABOLISM; MOUSE; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BREAST NEOPLASMS; CELL SURVIVAL; EPITHELIAL CELLS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; NEOPLASTIC STEM CELLS; NF-KAPPA B; RECEPTOR, ERBB-2; SIGNAL TRANSDUCTION;

EID: 84860864158     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2886     Document Type: Review

References (42)

1. Hayden MS, Ghosh S. Shared principles in NF-kappa B signaling. Cell 2008, 132:344-362. 10.1016/j.cell.2008.01.020, 18267068.
2. Karin M, Lin A. NF-kappa B at the crossroads of life and death. Nat Immunol 2002, 3:221-227.
3. Brantley DM, Chen CL, Muraoka RS, Bushdid PB, Bradberry JL, Kittrell F, Medina D, Matrisian LA, Kerr LD, Yull FE. Nuclear factor-kB (NF-kB) regulates proliferation and branching in mouse mammary epithelium. Mol Biol Cell 2001, 12:1445-1455. 34596, 11359934.
4. Cao YX, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin M. IKK alpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. Cell 2001, 107:763-775. 10.1016/S0092-8674(01)00599-2, 11747812.
5. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE. Aberrant nuclear factor-kappa B/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997, 100:2952-2960. 10.1172/JCI119848, 508506, 9399940.
6. Biswas DK, Shi Q, Baily S, Strickland I, Ghosh S, Pardee AB, Iglehart JD. NF-kB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 2004, 101:10137-10142. 10.1073/pnas.0403621101, 454178, 15220474.
7. Nakshatri H, BhatNakshatri P, Martin DA, Goulet RJ, Sledge GW. Constitutive activation of NF-kappa B during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997, 17:3629-3639. 232215, 9199297.
8. Connelly L, Barham W, Onishko HM, Sherrill T, Chodosh LA, Blackwell TS, Yull FE. Inhibition of NF-kappa B activity in mammary epithelium increases tumor latency and decreases tumor burden. Oncogene 2011, 30:1402-1412. 10.1038/onc.2010.521, 21076466.
9. Huber MA, Azoitei N, Baumann B, Grunert S, Sommer A, Pehamberger H, Kraut N, Beug H, Wirth T. NF-kappa B is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest 2004, 114:569-581. 503772, 15314694.
10. Chua HL, Bhat-Nakshatri P, Clare SE, Morimiya A, Badve S, Nakshatri H. NF-kappa B represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 2007, 26:711-724. 10.1038/sj.onc.1209808, 16862183.
11. Dejardin E, Bonizzi G, Bellahcene A, Castronovo V, Merville MP, Bours V. Highly-expressed P100/P52 (Nfkb2) sequesters other Nf-Kappa-B-related proteins in the cytoplasm of human breast-cancer cells. Oncogene 1995, 11:1835-1841.
12. Cogswell PC, Guttridge DC, Funkhouser WK, Baldwin AS. Selective activation of NF-kappa B subunits in human breast cancer: potential roles for NF-kappa B2/p52 and for Bcl-3. Oncogene 2000, 19:1123-1131. 10.1038/sj.onc.1203412, 10713699.
13. Demicco EG, Kavanagh KT, Romieu-Mourez R, Wang XB, Shin SR, Landesman-Bollag E, Seldin DC, Sonenshein GE. RelB/p52 NF-kappa B complexes rescue an early delay in mammary gland development in transgenic mice with targeted superrepressor I kappa B-alpha expression and promote carcinogenesis of the mammary gland. Mol Cell Biol 2005, 25:10136-10147. 10.1128/MCB.25.22.10136-10147.2005, 1280249, 16260626.
14. Connelly L, Robinson-Benion C, Chont M, Saint-Jean L, Li HJ, Polosukhin VV, Blackwell TS, Yull FE. A transgenic model reveals important roles for the NF-kappa B alternative pathway (p100/p52) in mammary development and links to tumorigenesis. J Biol Chem 2007, 282:10028-10035. 10.1074/jbc.M611300200, 17261585.
15. Wang XB, Belguise K, Kersual N, Kirsch KH, Mineva ND, Galtier F, Chalbos D, Sonenshein GE. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007, 9:470-U197. 10.1038/ncb1559, 2394707, 17369819.
16. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 2000, 97:8542-8547. 10.1073/pnas.97.15.8542, 26984, 10900013.
17. Sethi G, Ahn KS, Chaturvedi MM, Aggarwal BB. Epidermal growth factor (EGF) activates nuclear factor-kappa B through I kappa B alpha kinase-independent but EGF receptor-kinase dependent tyrosine 42 phosphorylation of I kappa B alpha. Oncogene 2007, 26:7324-7332. 10.1038/sj.onc.1210544, 17533369.
18. Huang L, Verstrepen L, Heyninck K, Wullaert A, Revets H, De Baetselier P, Beyaert R. ABINs inhibit EGF receptor-mediated NF-kappa B activation and growth of EGF receptor-overexpressing tumour cells. Oncogene 2008, 27:6131-6140. 10.1038/onc.2008.208, 18622428.
19. Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, Hirozane-Kishikawa T, Hill DE, Vidal M, Meyerson M, Grenier JK, Hinkle G, Root DE, Roberts TM, Lander ES, Polyak K, Hahn WC. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007, 129:1065-1079. 10.1016/j.cell.2007.03.052, 17574021.
20. Eddy SF, Guo SQ, Demicco EG, Romieu-Mourez R, Landesman-Borag E, Seldin DC, Sonenshein GE. Inducible I kappa B kinase/I kappa B kinase epsilon expression is induced by CK2 and promotes aberrant nuclear factor-kappa B activation in breast cancer cells. Cancer Res 2005, 65:11375-11383. 10.1158/0008-5472.CAN-05-1602, 16357145.
21. Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKK epsilon promotes cell transformation. Mol Cell 2009, 34:461-472. 10.1016/j.molcel.2009.04.031, 2746958, 19481526.
22. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, Schott A, Hayes D, Birnbaum D, Wicha MS, Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
23. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, Birnbaum D, Wicha MS. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313. 10.1158/0008-5472.CAN-08-2741, 2819227, 19190339.
24. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
25. Liu SL, Dontu G, Wicha MS. Mammary stem cells, self-renewal pathways, and carcinogenesis. Breast Cancer Res 2005, 7:86-95. 10.1186/bcr1021, 1143566, 15987436.
26. Korkaya H, Paulson A, Iovino F, Wicha MS. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130. 10.1038/onc.2008.207, 2602947, 18591932.
27. Merkhofer EC, Cogswell P, Baldwin AS. Her2 activates NF-kappa B and induces invasion through the canonical pathway involving IKK alpha. Oncogene 2010, 29:1238-1248. 10.1038/onc.2009.410, 2829103, 19946332.
28. Liu M, Sakamaki T, Casimiro MC, Willmarth NE, Quong AA, Ju X, Ojeifo J, Jiao X, Yeow WS, Katiyar S, Shirley LA, Joyce D, Lisanti MP, Albanese C, Pestell RG. The canonical NF-kappa B pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion. Cancer Res 2010, 70:10464-10473. 10.1158/0008-5472.CAN-10-0732, 21159656.
29. Cao YX, Luo JL, Karin M. I kappa B kinase a kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. Proc Natl Acad Sci USA 2007, 104:15852-15857. 10.1073/pnas.0706728104, 2000410, 17890319.
30. Schramek D, Leibbrandt A, Sigl V, Kenner L, Pospisilik JA, Lee HJ, Hanada R, Joshi PA, Aliprantis A, Glimcher L, Pasparakis M, Khokha R, Ormandy CJ, Widschwendter M, Schett G, Penninger JM. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102. 10.1038/nature09387, 3084017, 20881962.
31. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 2010, 468:103-107. 10.1038/nature09495, 20881963.
32. Pratt MAC, Tibbo E, Robertson SJ, Jansson D, Hurst K, Perez-Iratxeta C, Lau R, Niu MY. The canonical NF-kappa B pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene 2009, 28:2710-2722. 10.1038/onc.2009.131, 19483731.
33. Visvader JE. Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. Gene Dev 2009, 23:2563-2577. 10.1101/gad.1849509, 2779757, 19933147.
34. Naugler WE, Karin M. NF-kappa B and cancer - identifying targets and mechanisms. Curr Opin Genet Dev 2008, 18:19-26. 10.1016/j.gde.2008.01.020, 2587362, 18440219.
35. Iliopoulos D, Hirsch HA, Struhl K. An epigenetic switch involving NF-kappa B, Lin28, Let-7 microRNA, and IL6 links inflammation to cell transformation. Cell 2009, 139:693-706. 10.1016/j.cell.2009.10.014, 2783826, 19878981.
36. Jeselsohn R, Brown NE, Arendt L, Klebba I, Hu MG, Kuperwasser C, Hinds PW. Cyclin D1 kinase activity is required for the self-renewal of mammary stem and progenitor cells that are targets of MMTV-ErbB2 tumorigenesis. Cancer Cell 2010, 17:65-76. 10.1016/j.ccr.2009.11.024, 2818730, 20129248.
37. Chariot A. The NF-kappa B-independent functions of IKK subunits in immunity and cancer. Trends Cell Biol 2009, 19:404-413. 10.1016/j.tcb.2009.05.006, 19648011.
38. Visvader JE. Cells of origin in cancer. Nature 2011, 469:314-322. 10.1038/nature09781, 21248838.
39. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, Asselin-Labat ML, Gyorki DE, Ward T, Partanen A, Feleppa F, Huschtscha LI, Thorne HJ, , Fox SB, Yan M, French JD, Brown MA, Smyth GK, Visvader JE, Lindeman GJ. kConFab Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med 2009, 15:907-913. 10.1038/nm.2000, 19648928, kConFab.
40. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, Mackay A, Grigoriadis A, Tutt A, Ashworth A, Reis-Filho JS, Smalley MJ. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 2010, 7:403-417. 10.1016/j.stem.2010.07.010, 20804975.
41. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127. 10.1016/j.ccr.2004.06.022, 15324695.
42. Iwai K, Tokunaga F. Linear polyubiquitination: a new regulator of NF-kappa B activation. EMBO Rep 2009, 10:706-713. 10.1038/embor.2009.144, 2727427, 19543231.